Pharming Group (OTCMKTS:PHGUF) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, ValuEngine reports.
Separately, Zacks Investment Research upgraded shares of Pharming Group from a “sell” rating to a “hold” rating in a research note on Tuesday, March 10th.
OTCMKTS:PHGUF opened at $1.07 on Wednesday. Pharming Group has a 1 year low of $0.79 and a 1 year high of $1.82. The firm has a 50 day moving average of $1.29 and a 200-day moving average of $1.43. The stock has a market capitalization of $713.50 million, a P/E ratio of 17.83 and a beta of 1.58.
Pharming Group Company Profile
Pharming Group N.V., a specialty pharmaceutical company, develops and produces human therapeutic proteins for the treatment of rare diseases and unmet medical needs. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of angioedema attacks in patients with acute hereditary angioedema (HAE) in Europe, the United States, Israel, European Union countries, Norway, Iceland, and Liechtenstein.
Recommended Story: S&P/TSX Index
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.